Parkin: Much More than a Simple Ubiquitin LigaseAlves da Costa C. · Checler F.
Institut de Pharmacologie Moléculaire et Cellulaire et Institut de NeuroMédecine Moléculaire, Equipe Labellisée Fondation pour la Recherche Médicale, Sophia-Antipolis, Valbonne, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Parkin is mainly a cytosolic protein involved in a subset of Parkinson’s disease (PD) cases referred to as autosomal juvenile recessive forms of PD. Most studies have established as a dogma that parkin function could be resumed as an ubiquitin ligase activity. Accordingly, several cellular functions ascribed to parkin derive from its ability to ubiquitinate a series of proteins, thereby rendering them prone to proteasomal degradation. Several lines of data indicated that parkin could display antiapoptotic properties and we demonstrated that indeed, parkin could downregulate the p53-dependent pathway. However, we showed that such function remained independent of parkin’s ability to act as an ubiquitin ligase. Thus, we established that parkin repressed p53 transcription by physically interacting with its promoter. Here, we describe this novel parkin-associated transcription factor function and we speculate on putative additional transcriptional targets.
© 2011 S. Karger AG, Basel
- Agid Y, Arnulf I, Bejjani P, Bloch F, Bonnet AM, Damier P, Dubois B, Francois C, Houeto JL, Iacono D, Karachi C, Mesnage V, Messouak O, Vidailhet M, Welter ML, Yelnik J: Parkinson’s disease is a neuropsychiatric disorder. Adv Neurol 2003;91:365–370.
- Vidailhet M: Movement disorders in 2010: Parkinson disease-symptoms and treatments. Nat Rev Neurol 2011;7:70–72.
- Caviness JN, Lue L, Adler CH, Walker DG: Parkinson’s disease dementia and potential therapeutic strategies. CNS Neurosci Ther 2011;17:32–44.
- Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M, Machida Y, Mochizuki H: Progress in the pathogenesis and genetics of Parkinson’s disease. Philos Trans R Soc Lond B Biol Sci 2008;363:2215–2227.
- Martin I, Dawson VL, Dawson TM: Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 2011;12:301–325.
- Gasser T: Genetics of Parkinson’s disease. Clin Genet 1998;54:259–265.
- Lesage S, Brice A: Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48–R59.
- Martin I, Dawson VL, Dawson TM: The impact of genetic research on our understanding of Parkinson’s disease. Prog Brain Res 2010;183:21–41.
- Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C: Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010;31:763–780.
- Hartmann A, Hirsch EC: Parkinson’s disease. The apoptosis hypothesis revisited. Adv Neurol 2001;86:143–153.
- Dawson TM, Dawson VL: The role of parkin in familial and sporadic Parkinson’s disease. Mov Disord 2010;25(suppl 1):S32–S39.
- Jiang H, Ren Y, Zhao J, Feng J: Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 2004;13:1745–1754.
- Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G: Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004;131:2183–2194.
- Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302–305.
- da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A, Safe S, Abou-Sleiman PM, Wood NW, Takahashi H, Goldberg MS, Shen J, Checler F: Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson’s disease. Nat Cell Biol 2009;11:1370–1375.
- da Costa CA, Checler F: A novel parkin-mediated transcriptional function links p53 to familial Parkinson’s disease. Cell Cycle 2010;9:16–17.
- Alves da Costa C, Ancolio K, Checler F: Wild-type but not Parkinson’s disease-related ala-53–>Thr mutant α-synuclein protect neuronal cells from apoptotic stimuli. J Biol Chem 2000;275:24065–24069.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.